Instrument Inactif

Communiqués Repros Therapeutics Inc

Actions

US76028H2094

Recherche biotechnologique et médicale

Communiqués

26/01/18	Repros Announces Negative Opinion From the EMA for Enclomiphene	GL
15/12/17	Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency	GL
12/12/17	REPROS THERAPEUTICS INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout	BU
12/12/17	Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Repros Therapeutics Inc. to Allergan plc is Fair to Shareholders	BU
12/12/17	Repros Therapeutics Inc.® Announces Acquisition by Allergan plc	GL
13/11/17	Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results	GL
14/08/17	Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results	GL
17/07/17	Goldberg Law PC Announces an Investigation of Repros Therapeutics Inc.	BU
17/07/17	Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA	GL
18/05/17	Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock	GL
17/05/17	Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock	GL
09/05/17	Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results	GL
17/04/17	Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions	GL
10/04/17	Repros Names Larry Dillaha, M.D., its Permanent President and CEO	GL
10/04/17	Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids	GL
31/03/17	Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results	GL
02/02/17	Repros Announces New CEO	GL
30/01/17	FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the Treatment of Uterine Fibroids	GL
19/12/16	Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Endometriosis	GL
12/12/16	Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of Symptomatic Uterine Fibroids	GL
07/12/16	FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism	GL
14/11/16	Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered Orally and Vaginally for the Treatment of Uterine Fibroids	GL
08/11/16	Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results	GL
05/10/16	Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities	GL
26/09/16	FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism	GL